Syndicated Loan to Replenish Funds Used for the U.S. Podiatry Acquisition
First written in FY2025-H1. 4 of 5 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-07-30.
22 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Cash flows from financing activities were an inflow of ¥5,957 million, compared with an outflow of ¥7,599 million in the previous fiscal year. This was mainly due to ¥11,700 million in proceeds from long-term borrowings associated with the execution of a syndicated loan for domestic hospice construction and overseas business funding, including U.S. M&A.」
Long-term borrowings of ¥11,700 million were drawn under the syndicated loan signed in July 2025, advancing funding for hospice construction and U.S. M&A. - FY2026-H1AdvancedAnnual report
「For domestic hospice construction funding and the acquisition of overseas clinics and other overseas business funding, the Board of Directors resolved on 22 July 2025 to enter into a syndicated loan agreement, which was signed on 28 July 2025.」
A new syndicated loan was entered into to fund domestic hospice construction, overseas clinic acquisitions and overseas operations. Tranche A is ¥9.7 billion and Tranche B is ¥7.0 billion. - FY2025-H1First statedAnnual report
「To replenish funds contributed for the acquisition of the U.S. podiatry business in January 2024, the Board of Directors resolved on 30 May 2024 to enter into a syndicated loan agreement, which was signed on 5 June 2024. Total borrowings: ¥7,000 million. Maturity date: 7 June 2034.」
The company first disclosed a syndicated loan totaling ¥7,000 million from 9 financial institutions to replenish funds used for the U.S. podiatry acquisition.